Investigators in Brazil concluded that the severity of COVID-19 did not differ among patients with atopic dermatitis, chronic urticaria , psoriasis, and vitiligo. However, but acute COVID-19 and its treatments was linked to changes in the course of skin diseases.<\/p>\n
In a letter to the editor, Helio Miot, MD, PhD, a Professor of Dermatology at Unesp Botucatu, Sao Paulo state, Brazil, and fellow investigators noted that among COVID-19 complications, the inflammation caused by it could influence the skin microenvironment.<\/p>\n
Limited information was available on the influence of COVID-19 and its treatments on patients with cutaneous diseases, though it was hypothesized that dermatolicial conditions could be affected by the virus.<\/p>\n
Miot and colleagues conducted an electronic survey to evaluate acute COVID-19 symptoms, treatment, and changes as they related to the psoriasis, vitiligo, atopic dermatitis, and chronic urticaria.<\/p>\n
Miot and investigators analyzed 6614 confirmed COVID-19 cases between May and June 2021.<\/p>\n
Of the total number of cases, 843 reported 1 of the 4 active skin diseases.<\/p>\n
Via 88,648 SMS messages and online support groups, investigators contacted these participants to engage in an online questionnaire regarding COVID-19 and the featured skin diseases.<\/p>\n
Associations among dermatological treatments for the featured diseases and COVID-19 severity, symptomatic period, and clinical course were studied.<\/p>\n
Overall, hospitalization due to COVID-19 did not differ between respondents with (9%) and without (11%) skin diseases, though a lower rate of hospitalization was noted for respondents with vitiligo who used oral antioxidants.<\/p>\n
However, Miot and colleagues reported that some symptoms related to the virus were associated with various skin diseases.<\/p>\n
High fever was associated with an exacerbation of chronic urticaria, and severe dyspnea was associated with the worsening of arthralgia in psoriasis and atopic dermatitis lesions.<\/p>\n
Additionally, the use of antimalarials for COVID-19 was shown in the exacerbation of vitiligo, and hydroxychloroquine was associated with clinical worsening.<\/p>\n
Oral corticosteroids also lead to greater clinical impairment in respondents with vitiligo and chronic urticaria, as did antihistamines for those with atopic dermatitis.<\/p>\n
Antihistamines were also associated with longer symptomatic periods in cases of acute COVID-19, however methotrexate and biologics had no detectable effect on the virus.<\/p>\n
Several other important developments were recorded during the study.<\/p>\n
Miot and investigators believed the use of oral glucocorticoids, which were used in cases of unstable vitiligo and chronic urticaria, indicated increased exacerbation caused by viral infection.<\/p>\n
They added that the clinical worsening of chronic urticaria by COVID-19 was the possible influence of TGF - secretion. The event led to fatigue, fever, cough, and pneumonia, and was associated with high fever as well.<\/p>\n
The acute-phase protein EL-6 was also linked to COVID-19 symptoms.<\/p>\n
The severity of COVID-19 does not differ among patients with AD, CU, psoriasis, and vitiligo, but acute COVID-19 and its treatments can affect the course of skin diseases, the team wrote.<\/p>\n
The letter, COVID-19 and skin diseases: results from a survey of 843 patients with atopic dermatitis, psoriasis, vitiligo, and chronic urticaria, was published online in the Journal of The European Academy of Dermatology and Venereology.<\/p>\n
<\/p>\n
Continue reading here: Investigators in Brazil concluded that the severity of COVID-19 did not differ among patients with atopic dermatitis, chronic urticaria , psoriasis, and vitiligo. However, but acute COVID-19 and its treatments was linked to changes in the course of skin diseases. Continue reading
\nCOVID-19 Linked to Exacerbations in Skin Diseases - MD Magazine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"